<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> facilitates development and progression of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> such as <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> (LVH), <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD), <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Strict blood pressure control over 24 hours is essential for the primary and secondary prevention of these <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Inhibitors of renin-angiotensin system(RASI) such as <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blockers(ARB) and long-acting <z:chebi fb="0" ids="38215">calcium channel blockers</z:chebi>(CCB) are effective in improving LVH </plain></SENT>
<SENT sid="3" pm="."><plain>CCB and beta-blockers are preferentially chosen for CAD </plain></SENT>
<SENT sid="4" pm="."><plain>RASI is expected to reduce the incidence of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RASI, beta-blockers and <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> blockers have been shown to improve the prognosis of <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:chebi fb="40" ids="35498">diuretics</z:chebi> and long-acting CCB are used for the adequate control of body fluid volume and blood pressure </plain></SENT>
</text></document>